Pregnancy Surveillance Program of Patients Exposed to Epidiolex/Epidyolex During Pregnancy
NCT06113237
Recruiting
The purpose of this study is to evaluate pregnancy-related health outcomes in participants who are exposed to Epidiolex/Epidyolex during pregnancy and their infant up to 12 months of life.
Gender:
FEMALE
Ages:
All
Trial Updated:
04/02/2025
Locations: United Biosource LLC, Morgantown, West Virginia
Conditions: Maternal Complications, Pregnancy Complication, Birth Outcomes, Adverse, Pregnancy
Register for Updates
Preventing Suicidal Behavior With Diverse High-Risk Youth in Acute Care Settings
NCT06151158
Recruiting
The study will compare the effectiveness of two relatively brief and scalable evidence-based interventions: the Stanley Brown Safety Planning Intervention and Follow-up Contacts (SPI+), a suicide-specific intervention that helps people prevent suicidal crises from escalating, and Interpersonal Psychotherapy for Adolescents Ultra Short Crisis Intervention (IPT-A SCI), a psychotherapeutic crisis intervention treatment for suicidal adolescents that teaches youth skills to prevent suicidal crises an... Read More
Gender:
ALL
Ages:
Between 12 years and 19 years
Trial Updated:
04/02/2025
Locations: Johns Hopkins All Children's Hospital, Saint Petersburg, Florida +5 locations
Conditions: Suicide, Attempted, Suicide Ideation, Suicide, Suicide Prevention
Register for Updates
A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis
NCT06260163
Recruiting
The purpose of this study is to evaluate the efficacy of guselkumab in pediatric participants with moderately to severely active ulcerative colitis at the end of maintenance therapy among participants who were induction responders.
Gender:
ALL
Ages:
Between 2 years and 17 years
Trial Updated:
04/02/2025
Locations: Riley Hospital for Children, Indianapolis, Indiana +59 locations
Conditions: Colitis, Ulcerative
Register for Updates
Preeclampsia Educational Program Study (PrEPS)
NCT06373367
Recruiting
Preeclampsia complicates approximately 8% of all pregnancies. A critical factor of outpatient monitoring is patient education; specifically, education regarding nature of the disease, ongoing short- and long-term risks, and warning signs and symptoms for worsening of disease. This study aims to compare patient knowledge using a novel illustration based app compared to standard discharge instructions.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
04/02/2025
Locations: MemorialCare Long Beach Medical Center, Long Beach, California
Conditions: Preeclampsia, Preeclampsia Severe, Preeclampsia Mild, Preeclampsia Postpartum
Register for Updates
Tislelizumab in People With Colorectal Cancer
NCT06529523
Recruiting
The researchers are doing this study to find out whether tislelizumab is an effective treatment for people with colorectal cancer who are living in Nigeria. The researchers will also look at the safety of the study drug. All participants in this study will be treatment naïve (they have not yet received treatment for their cancer), and their cancer will be mismatch repair deficient (dMMR). dMMR cancer can happen when your cells are unable to repair mistakes made during the cell division process. Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/02/2025
Locations: Memorial Sloan Kettering Cancer Center, New York, New York +2 locations
Conditions: Colorectal Cancer
Register for Updates
A Study to Test Long-term Treatment With Brigimadlin in People With Solid Tumours Who Took Part in a Previous Study With This Medicine
NCT06619509
Recruiting
This study is open to adults who participated in a previous clinical study with brigimadlin. The goal of this study is to find out how well people with solid tumours tolerate long-term treatment with brigimadlin. Brigimadlin is a so-called MDM2 inhibitor that is being developed to treat cancer. Participants are grouped in cohorts depending on their treatment in the previous study: * Cohort 1a got brigimadlin and continues treatment with brigimadlin * Cohort 1b got brigimadlin for 4 or less tr... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/02/2025
Locations: Precision NextGen Oncology, Beverly Hills, California +41 locations
Conditions: Solid Tumours
Register for Updates
Puberty, Testosterone, and Brain Development
NCT06670053
Recruiting
Transmasculine youth (female sex assigned at birth, male gender identity) who begin clinical gender affirming hormone therapy (GAHT) with testosterone (T) may experience changes in headache. Researchers think this because studies published on effects of giving testosterone to cisgender females (female sex, female gender identity) and transmasculine adults seem to show an effect on pain. This research will help us learn more about changes in headache and in brain structure and function in transm... Read More
Gender:
ALL
Ages:
Between 12 years and 20 years
Trial Updated:
04/02/2025
Locations: Children's Hospital Colorado, Aurora, Colorado
Conditions: Gender Identity, Gender Dysphoria in Adolescents and Adults, Headache, Transgender
Register for Updates
REVITALIZE: RCT to Reduce Fatigue in Adults With Ovarian Cancer on PARP Inhibitors
NCT06710548
Recruiting
The purpose of this study is to see whether a supportive intervention (REVITALIZE) reduces fatigue and its impact on daily life and activities for participants with ovarian cancer taking PARP inhibitors. The name of the study groups in this research study are: 1. REVITALIZE 2. Educational Materials
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
04/02/2025
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts
Conditions: Ovarian Cancer, Advanced Ovarian Carcinoma, Fallopian Tube Carcinoma, Primary Peritoneal Cancer, PARP Inhibitor, Fatigue Related to Cancer Treatment, Fatigue in Cancer Survivors
Register for Updates
A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors
NCT06777316
Recruiting
This is an open-label, phase 1/2 study evaluating the safety, tolerability, pharmacokinetic (what the body does to the drug), pharmacodynamic (what the drug does to the body), and antitumor activity of CGT4859 in adult participants with intrahepatic cholangiocarcinoma (iCCA) or other advanced solid tumors with FGFR2 and/or FGFR3 genetic alternations.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/02/2025
Locations: Stanford Cancer Institute, Palo Alto, California +7 locations
Conditions: Intrahepatic Cholangiocarcinoma (Icc), Cholangiocarcinoma, Other Solid Tumors, Adult, FGFR2 Gene Fusion/Rearrangement, FGFR2 Gene Amplification, FGFR2 Gene Short Variants, FGFR3 Gene Fusion/Rearrangement, FGFR3 Gene Amplification, FGFR3 Gene Short Variants, FGFR2 Genetic Alterations, FGFR3 Genetic Alterations, Advanced Solid Tumors
Register for Updates
Intracept Minimally-invasive PROcedure for VErtebrogenic Back Pain
NCT06827262
Recruiting
Compile real-world outcomes of commercially approved Intracept™ Intraosseous Nerve Ablation Systems in the treatment of patients diagnosed with vertebrogenic pain.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/02/2025
Locations: MarinHealth Spine Institute, Larkspur, California +1 locations
Conditions: Chronic Low-back Pain, Vertebrogenic Pain Syndrome
Register for Updates
A Single-session Intervention Adaptation of the Habit Framework for the Prevention of Eating Disorders
NCT06861608
Recruiting
The purpose of this proposal is to launch the first trial of a single-session intervention (SSI) specifically for the prevention of eating disorders (EDs).
Gender:
ALL
Ages:
Between 18 years and 22 years
Trial Updated:
04/02/2025
Locations: Virginia Commonwealth University, Richmond, Virginia
Conditions: Eating Disorder Not Otherwise Specified
Register for Updates
Drug-Drug Interaction Potential of Mavorixafor
NCT06914869
Recruiting
The main purpose of this study is to evaluate drug-drug interaction (DDI) of orally administered mavorixafor with cytochrome P3A (CYP3A) inducers carbamazepine (a strong CYP3A inducer) or efavirenz (a moderate CYP3A inducer) in healthy male and female participants.
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
04/02/2025
Locations: Parexel International LLC, Baltimore, Maryland
Conditions: Healthy Participants
Register for Updates